Gastrointestinal stromal tumor workshop
J Berman, TJ O'Leary - Human pathology, 2001 - Elsevier
Gastrointestinal stromal tumor (GIST) has emerged in the past year as a prototypical
neoplasm that responds to therapy directed against a single target molecule-the KIT
receptor tyrosine kinase protein. Although GIST seldom responds to conventional
chemotherapeutic agents, early experience with the tyrosine kinase inhibitor, STI-571
(Gleevec; Novartis, Basel, Switzerland), has been extremely encouraging. Early results have
appeared in a recent case report in the New England Journal of Medicine (April 5, 2001) …
neoplasm that responds to therapy directed against a single target molecule-the KIT
receptor tyrosine kinase protein. Although GIST seldom responds to conventional
chemotherapeutic agents, early experience with the tyrosine kinase inhibitor, STI-571
(Gleevec; Novartis, Basel, Switzerland), has been extremely encouraging. Early results have
appeared in a recent case report in the New England Journal of Medicine (April 5, 2001) …